

**Set Name Query**

side by side

**Hit Count Set Name**

result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*L7 L6 same (cd40 or cd40L or cd40 adj ligand or cd20 or gp39)79 L7L6 ('24-31' or '89-76' or 'c2b8') same (antibod\$ or hybridoma\$)108 L6*DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*L5 (cd20) same (cd40L or cd40 adj ligand or gp39) and (leukemi\$)2 L5*DB=USPT,PGPB; PLUR=YES; OP=ADJ*L4 (cd20) same (cd40L or cd40 adj ligand or gp39) and (leukemi\$)33 L4L3 L1 and (cd20 or cd40 or cd40L or cd40 adj ligand or gp39)28 L3L2 L1 and (leukemi\$)33 L2L1 hanna-nabil\$44 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 33 returned.**

- 
- ☐ 1. [20030119029](#). 13 Aug 02. 26 Jun 03. Compositions and methods relating to novel benzodiazepine compounds and targets thereof. Glick, Gary D., et al. 435/6; 435/235.1 435/325 514/221 A61K031/5513 C12Q001/68 A61K031/55 A01N043/62 C12N007/00 C12N007/01 C12N005/00 C12N005/02.
- 
- ☐ 2. [20030118592](#). 25 Jul 02. 26 Jun 03. Binding domain-immunoglobulin fusion proteins. Ledbetter, Jeffrey A., et al. 424/178.1; 530/391.1 A61K039/395 C07K016/46.
- 
- ☐ 3. [20030103971](#). 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.
- 
- ☐ 4. [20030059763](#). 26 Jan 01. 27 Mar 03. Immunoglobulin class switch recombination. Saxon, Andrew, et al. 435/4; C12Q001/00.
- 
- ☐ 5. [20030012781](#). 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
- 
- ☐ 6. [20030008342](#). 16 Nov 99. 09 Jan 03. SURFACE RECEPTOR ANTIGEN VACCINES. Scholler, Nathalie B., et al. 435/69.1; 435/320.1 536/23.1 C07H021/04 C12P021/02 C12N015/74.
- 
- ☐ 7. [20020197256](#). 14 Mar 02. 26 Dec 02. Combination therapy. Grewal, Iqbal. 424/144.1; 424/155.1 A61K039/395.
- 
- ☐ 8. [20020164346](#). 14 Feb 02. 07 Nov 02. Altered peptide ligands. Nicolette, Charles A.. 424/185.1; A61K039/00.
- 
- ☐ 9. [20020147312](#). 30 Jan 02. 10 Oct 02. Hybrid antibodies and uses thereof. O'Keefe, Theresa, et al. 530/387.3; 530/388.15 C07K016/28.
- 
- ☐ 10. [20020065241](#). 10 Aug 01. 30 May 02. Antigenic peptide concatomers. Shankara, Srinivas. 514/44; 424/450 424/93.21 536/23.5 A61K048/00 C07H021/04 A61K009/127.
- 

[Generate Collection](#)[Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 20 of 33 returned.**

- 
- ☐ 11. [20020058029](#). 18 Sep 01. 16 May 02. Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination. Hanna, Nabil. 424/131.1; 424/144.1 A61K039/395.
- 
- ☐ 12. [20020031522](#). 10 Mar 97. 14 Mar 02. TRUNCATED CRAFI INHIBITS CD40 SIGNALING. BALTIMORE, DAVID, et al. 424/185.1; 435/63 435/64 435/7.2 435/7.23 530/324 530/350 530/358 G01N033/53 G01N033/567 G01N033/574 C12P031/00 C12P029/00 A61K039/00 C07K005/00 C07K007/00 C07K016/00 C07K017/00 A61K038/00 C07K001/00 C07K014/00 A61K038/16.
- 
- ☐ 13. [20020028178](#). 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
- 
- ☐ 14. [20020018766](#). 05 Apr 01. 14 Feb 02. Genes differentially expressed in cancer cells to design cancer vaccines. Roberts, Bruce L., et al. 424/93.21; 424/155.1 424/85.1 435/6 A61K048/00 C12Q001/68 A61K039/395 A61K038/19.
- 
- ☐ 15. [20020009444](#). 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.
- 
- ☐ 16. [20020006404](#). 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.
- 
- ☐ 17. [20010056066](#). 13 Jul 01. 27 Dec 01. Method of treating immune cell mediated systemic diseases. Bugelski, Peter John, et al. 514/8; 424/131.1 A61K038/16 A61K039/395.
- 
- ☐ 18. [20010018041](#). 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.
- 
- ☐ 19. [6569997](#). 25 May 00; 27 May 03. Antibody specific for H4-1BB. Kwon; Byoung S.. 530/388.22; 424/130.1 424/184.1 435/252.3 435/6 435/69.1 435/69.5 435/7.2 435/7.21 436/501 530/350 536/23.5. C07K016/00.
- 
- ☐ 20. [6506383](#). 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
- 

[Generate Collection](#)[Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 30 of 33 returned.**

- 
- ☐ 21. [6465251](#). 13 Nov 96; 15 Oct 02. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin. Schultze; Joachim L., et al. 435/377; 435/2 435/325 435/326 435/352 435/355 435/363 435/366 435/372 435/372.1 435/372.2 435/374 435/375 435/376 435/383. C12N005/02 C12N005/06 C12N005/08 C12N005/12.
- 
- ☐ 22. [6440418](#). 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
- 
- ☐ 23. [6303121](#). 14 Jan 98; 16 Oct 01. Method of using human receptor protein 4-1BB. Kwon; Byoung S.. 424/141.1; 424/138.1 424/139.1 424/144.1 530/350 530/351 530/388.22. A01N037/18 A61K038/00 A61K039/395.
- 
- ☐ 24. [6150584](#). 02 Oct 96; 21 Nov 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/18; 424/93.21 800/25 800/6. A61K048/00 C12N005/10 C12N015/07.
- 
- ☐ 25. [6106832](#). 22 Jan 96; 22 Aug 00. Treatment of individuals exhibiting defective CD40L. Spriggs; Melanie K., et al. 424/134.1; 424/184.1 424/192.1 424/195.11 514/2 514/8 514/885. A61K038/19.
- 
- ☐ 26. [6075181](#). 07 Jun 95; 13 Jun 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/25; 800/18 800/21 800/4 800/6. A61K048/00 C12N015/09 C12N005/10.
- 
- ☐ 27. [6001358](#). 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 536/23.53. A61K039/395 C07K016/28.
- 
- ☐ 28. [5877210](#). 05 Jun 95; 02 Mar 99. Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/178.1 424/179.1 424/181.1 435/184 435/244 556/1 556/42 556/44. A01N055/02 A61K039/395 C07F053/00.
- 
- ☐ 29. [5846998](#). 18 Jun 96; 08 Dec 98. Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/617 424/646 435/184 435/326 556/1 556/42 556/44. A01N055/02 A01N059/16 C12N009/99 C07F053/00.
- 
- ☐ 30. [5693627](#). 25 May 95; 02 Dec 97. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 514/137; 435/184 435/244 514/141 564/12 568/14 568/17. A61K031/66 C12N009/99 C12N001/38 C07F009/02.
- 

[Generate Collection](#)[Print](#)

Generate Collection

Print

**Search Results - Record(s) 31 through 33 of 33 returned.**

- ☐ 31. 5583242. 25 May 95; 10 Dec 96. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 556/44; 556/1 556/114 556/116 556/117 556/42. C07F005/00.
- ☐ 32. 5565491. 31 Jan 94; 15 Oct 96. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 514/492; 514/499 556/1 556/114 556/116 556/117 556/42 556/44. A61K031/28 A61K031/30 C07F001/08 C07F005/00.
- ☐ 33. 5565321. 21 Jan 94; 15 Oct 96. Detection of mutations in a CD40 ligand gene. Spriggs; Melanie K., et al. 435/6; 435/7.1 435/91.1 536/23.1 536/23.5 536/24.3 536/24.31. C12F019/34 C12Q001/68 G01N033/50.

Generate Collection

Print

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)[Next Page](#)

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40	2482
CD40S	0
CD40L	928
CD40LS	2
LIGAND	82251
LIGANDS	57709
CD20	1368
CD20S	0
GP39	275
GP39S	0
(6 SAME ((GP39 OR CD40L OR CD20 OR CD40) OR (CD40 ADJ LIGAND))).USPT,PGPB,JPAB,EPAB,DWPI.	79
(L6 SAME (CD40 OR CD40L OR CD40 ADJ LIGAND OR CD20 OR GP39)).USPT,PGPB,JPAB,EPAB,DWPI.	79

Database:

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Search:

L7

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE: Friday, June 27, 2003** [Printable Copy](#) [Create Case](#)

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)



Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)

[Next Page](#)

s (24(w)31 or 89(w)76 or c2b8) (20n) (antibod? or hybridoma?) and (Cd20 or cd40L or cd40(w)ligand or gp39)

1301928 24

503721 31

1050 24(W)31

201923 89

229499 76

94 89(W)76

263 C2B8

1807045 ANTIBOD?

47845 HYBRIDOMA?

210 ((24(W)31 OR 89(W)76) OR C2B8) (20N) (ANTIBOD? OR  
HYBRIDOMA?)

10006 CD20

4500 CD40L

18006 CD40

348210 LIGAND

8235 CD40(W)LIGAND

574 GP39

S8 179 (24(W)31 OR 89(W)76 OR C2B8) (20N) (ANTIBOD? OR HYBRIDOMA?)  
AND (CD20 OR CD40L OR CD40(W)LIGAND OR GP39)

? rd s8

...examined 50 records (50)

...examined 50 records (100)

...examined 50 records (150)

...completed examining records

S9 98 RD S8 (unique items)

? ds

Set	Items	Description
S1	31	AU='HANNA NABIL'
S2	31	RD S1 (unique items)
S3	3	S2 AND LEUKEMI?
S4	3	RD S3 (unique items)
S5	0	(CD20)(10N)(ANTIBOD?) AND (CD40L OR CD40(W)LIGAND OR GP39) - (10N)(ANTIBOD?) AND LEUKEMI?
S6	21	(CD20) AND (CD40L OR CD40(W)LIGAND OR GP39) AND LEUKEMI?
S7	19	RD S6 (unique items)
S8	179	(24(W)31 OR 89(W)76 OR C2B8) (20N) (ANTIBOD? OR HYBRIDOMA?) - AND (CD20 OR CD40L OR CD40(W)LIGAND OR GP39)
S9	98	RD S8 (unique items)
?		

begin 5,73,155,399  
27jun03 16:21:44 User208760 Session D2318.2  
\$0.00 0.070 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.01 TELNET  
\$0.01 Estimated cost this search  
\$0.32 Estimated total session cost 0.157 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2003/Jun.W4  
(c) 2003 BIOSIS

File 73:EMBASE 1974-2003/Jun W4  
(c) 2003 Elsevier Science B.V.

\*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 155:MEDLINE(R) 1966-2003/Jun W4  
(c) format only 2003 The Dialog Corp.

\*File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.

File 399:CA SEARCH(R) 1967-2003/UD=13826  
(c) 2003 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

? e ah=hanna nabil ?

Ref	Items	Index-term
E1	1	AD=990625
E2	1	AD=991127
E3	0	*AH=HANNA NABIL ?
E4	1	AN=AE 40
E5	1	AN=AM 105531
E6	1	AN=AM 20000032
E7	1	AN=AM 20000063
E8	1	AN=AM 20000084
E9	1	AN=AM 20010003
E10	1	AN=AM 2001077
E11	1	AN=AM 411
E12	1	AN=AM 412

Enter P or PAGE for more

? e au=hanna nabil ?

Ref	Items	Index-term
E1	6	AU=HANNA N.S.
E2	31	AU=HANNA NABIL
E3	0	*AU=HANNA NABIL ?
E4	1	AU=HANNA NADAR
E5	3	AU=HANNA NADER
E6	13	AU=HANNA NADER N
E7	4	AU=HANNA NAEEM
E8	5	AU=HANNA NAEEM B
E9	3	AU=HANNA NANCY
E10	1	AU=HANNA NASHAT F
E11	6	AU=HANNA NASSER
E12	4	AU=HANNA NASSER H

Enter P or PAGE for more

? s e2

S1 31 AU='HANNA NABIL'

? rd s1

...completed examining records

S2 31 RD S1 (unique items)  
? s s2 and leukemia?  
31 S2  
523094 LEUKEMI?  
S3 3 S2 AND LEUKEMI?  
? rd s3  
...completed examining records  
S4 3 RD S3 (unique items)  
? t s4/3/all

4/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13790357 BIOSIS NO.: 200200419178  
Induction of apoptosis by IDEC-152 (anti-CD23) in chronic lymphocytic  
leukemia.  
AUTHOR: Pathan Nuzhat(a); Hariharan Kandasamy; Berquist Lisa; Hopkins  
Michael; Saven Alan; Reff Mitchell; Grint Paul; **Hanna Nabil**  
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals, San Diego, CA\*\*USA  
JOURNAL: Proceedings of the American Association for Cancer Research Annual  
Meeting 43p1005 March, 2002  
MEDIUM: print  
CONFERENCE/MEETING: 93rd Annual Meeting of the American Association for  
Cancer Research San Francisco, California, USA April 06-10, 2002  
ISSN: 0197-016X  
RECORD TYPE: Citation  
LANGUAGE: English

4/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13557864 BIOSIS NO.: 200200186685  
Induction of apoptosis by IDEC-152 (anti-CD23) in lymphoma cells.  
AUTHOR: Pathan Nuzhat(a); Hariharan Kandasamy(a); Hopkins Michael; Saven  
Alan; Reff Mitchell(a); **Hanna Nabil**(a); Grint Paul(a)  
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals, San Diego, CA\*\*USA  
JOURNAL: Blood 98 (11 Part 1):p367a November 16, 2001  
MEDIUM: print  
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of  
Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001  
ISSN: 0006-4971  
RECORD TYPE: Abstract  
LANGUAGE: English

4/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

11217379 BIOSIS NO.: 199799838524  
Antigen formulation for recombinant cancer vaccines.  
AUTHOR: **Hanna Nabil**; Black Amelia; Hariharan Kandasamy  
AUTHOR ADDRESS: IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA  
92121\*\*USA  
JOURNAL: International Journal of Oncology 11 (SUPPL.):p924 1997  
CONFERENCE/MEETING: 2nd World Congress on Advances in Oncology Athens,  
Greece October 16-18, 1997  
ISSN: 1019-6439  
RECORD TYPE: Citation  
LANGUAGE: English  
? s (cd20) (10n) (antibod\$) and (cd40L or cd40(w)ligand or gp39) (10n)antibod?) and  
leukemi?

>>>Unmatched parentheses

? s (cd20)(10n)(antibod\$) and (cd40L or cd40(w)ligand or gp39)(10n)(antibod?) and leukemia?

10006 CD20  
0 ANTIBOD\$  
0 CD20(10N)ANTIBOD\$  
4500 CD40L  
18006 CD40  
348210 LIGAND  
8235 CD40(W)LIGAND  
574 GP39  
1807045 ANTIBOD?  
1788 ((CD40L OR CD40(W)LIGAND) OR GP39)(10N)ANTIBOD?  
523094 LEUKEMI?

S5 0 (CD20)(10N)(ANTIBOD\$) AND (CD40L OR CD40(W)LIGAND OR GP39)(10N)(ANTIBOD?) AND LEUKEMI?

? s (cd20) and (cd40L or cd40(w)ligand or gp39) and leukemia?

10006 CD20  
4500 CD40L  
18006 CD40  
348210 LIGAND  
8235 CD40(W)LIGAND  
574 GP39  
523094 LEUKEMI?

S6 21 (CD20) AND (CD40L OR CD40(W)LIGAND OR GP39) AND LEUKEMI?

? rd s6

...completed examining records

S7 19 RD S6 (unique items)

? t s7/3/all

7/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13107668 BIOSIS NO.: 200100314817

Enhancement of antibody dependent cellular cytotoxicity (ADCC) against malignant B cells by trimeric **CD40L**.

AUTHOR: Jia Li(a); Epstein Alan(a); Douer Dan(a); Mohrbacher Ann(a)

AUTHOR ADDRESS: (a)University of Southern California, Los Angeles, CA\*\*USA

JOURNAL: Blood 96 (11 Part 2):p288b-289b November 16, 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of

Hematology San Francisco, California, USA December 01-05, 2000

SPONSOR: American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

7/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

11447606 BIOSIS NO.: 199800228938

Chronic lymphocytic leukemia B cells can express **CD40**

**ligand** and demonstrate T-cell type costimulatory capacity.

AUTHOR: Schattner Elaine J(a); Mascarenhas John; Reyfman Inna; Koshy Mary;

Woo Caroline; Friedman Steven M; Crow Mary K

AUTHOR ADDRESS: (a)Room C-640, Cornell Univ. Med. Coll., 1300 York Ave.,

New York, NY 10021\*\*USA

JOURNAL: Blood 91 (8):p2689-2697 April 15, 1998

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract  
LANGUAGE: English

7/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

09615532 BIOSIS NO.: 199598070450  
In vitro culturing of **leukemic** B cells from CLL patients using feeder cells and **CD40 ligand**.  
AUTHOR: Buske C(a); Gogowski G; Feuring-Buske M; Koenemann S; Widmer M; Banchereau J; Lebien T W; Schreiber K; Hiddemann W; Woermann B  
AUTHOR ADDRESS: (a)Dep. Intern. Med., Univ. Goettingen, Goettingen\*\*Germany  
JOURNAL: Blood 84 (10 SUPPL. 1):p454A 1994  
CONFERENCE/MEETING: Abstracts Submitted to the 36th Annual Meeting of the American Society of Hematology Nashville, Tennessee, USA December 2-6, 1994  
ISSN: 0006-4971  
RECORD TYPE: Citation  
LANGUAGE: English

7/3/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

12085976 EMBASE No: 2003197250  
New directions in the diagnosis and treatment of chronic lymphocytic leukaemia  
Schriever F.; Huhn D.  
Dr. F. Schriever, Gartenstr. 26, 85456 Wartenberg Germany  
AUTHOR EMAIL: folke.schriever@t-online.de  
Drugs ( DRUGS ) (New Zealand) 2003, 63/10 (953-969)  
CODEN: DRUGA ISSN: 0012-6667  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 108

7/3/5 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

11654934 EMBASE No: 2002227184  
Immunotherapy of chronic lymphocytic **leukemia**  
Wierda W.G.; O'Brien S.  
S. O'Brien, UT MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Houston, TX 77030 United States  
Expert Review of Anticancer Therapy ( EXPERT REV. ANTICANCER THER. ) (United Kingdom) 2001, 1/1 (73-83)  
CODEN: ERATB ISSN: 1473-7140  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 94

7/3/6 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

11567455 EMBASE No: 2002139082  
Immunomodulatory gene therapy for haematological malignancies  
Schmidt-Wolf G.D.; Schmidt-Wolf I.G.H.

I.G.H. Schmidt-Wolf, Medizinische Univ. Klin./Poliklin. I,  
Sigmund-Freud-Str. 25, 53105 Bonn Germany  
AUTHOR EMAIL: picasso@uni-bonn.de  
British Journal of Haematology ( BR. J. HAEMATOL. ) (United Kingdom)  
2002, 117/1 (23-32)  
CODEN: BJHEA ISSN: 0007-1048  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 82

7/3/7 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

11493192 EMBASE No: 2002064859  
Surface antigen expression in chronic lymphocytic leukemia:  
Clustering analysis, interrelationships and effects of chromosomal  
abnormalities  
Hulkkonen J.; Vilpo L.; Hurme M.; Vilpo J.  
J. Vilpo, Department of Clinical Chemistry, Tampere University Hospital,  
PO Box 2000, FIN-33521 Tampere Finland  
Leukemia ( LEUKEMIA ) (United Kingdom) 2002, 16/2 (178-185)  
CODEN: LEUKE ISSN: 0887-6924  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 40

7/3/8 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

07642174 EMBASE No: 1999127877  
Expression of CD40/CD40 ligand and Bcl-2 family proteins in  
labial salivary glands of patients with Sjogren's syndrome  
Nakamura H.; Kawakami A.; Tominaga M.; Migita K.; Kawabe Y.; Nakamura T.;  
Eguchi K.  
Prof. K. Eguchi, First Dept. of Internal Medicine, Nagasaki University  
Sch. of Medicine, 1-7-1 Sakamoto, Nagasaki City, Nagasaki 852-8501 Japan  
Laboratory Investigation ( LAB. INVEST. ) (United States) 1999, 79/3  
(261-269)  
CODEN: LAINA ISSN: 0023-6837  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 29

7/3/9 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

09921324 21831292 PMID: 11842396  
Advances in classification and therapy of indolent B-cell malignancies.  
Kipps Thomas J  
Department of Medicine, University of California, San Diego School of  
Medicine, La Jolla, CA 92093, USA.  
Seminars in oncology (United States) Feb 2002, 29 (1 Suppl 2)  
p98-104, ISSN 0093-7754 Journal Code: 0420432  
Document type: Journal Article; Review; Review, Tutorial  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

7/3/10 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

138235807 CA: 138(16)235807a JOURNAL  
Surface antigen expression and correlation with variable heavy-chain gene  
mutation status in chronic lymphocytic leukemia  
AUTHOR(S): Vilpo, Juhani; Tobin, Gerard; Hulkkonen, Janne; Hurme, Mikko;  
Thunberg, Ulf; Sundstrom, Christer; Vilpo, Leena; Rosenquist, Richard  
LOCATION: Department of Clinical Chemistry, University of Tampere Medical  
School, Laboratory Center of Tampere University Hospital, Tampere, Finland  
JOURNAL: Eur. J. Haematol. (European Journal of Haematology) DATE: 2003  
VOLUME: 70 NUMBER: 1 PAGES: 53-59 CODEN: EJHAEC ISSN: 0902-4441  
LANGUAGE: English PUBLISHER: Blackwell Munksgaard

7/3/11 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

137336712 CA: 137(23)336712a PATENT  
Maturation of antigen-presenting cells using activated t cells  
INVENTOR(AUTHOR): Berenson, Ronald Jay; Bonyhadi, Mark; Craig, Stewart;  
Kalamasz, Dale; Monji, Tatsue  
LOCATION: USA  
ASSIGNEE: Xcyte Therapies, Inc.  
PATENT: PCT International ; WO 200287627 A1 DATE: 20021107  
APPLICATION: WO 2002US13616 (20020429) \*US PV287168 (20010427) \*US  
PV295331 (20010601)  
PAGES: 70 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A;  
C12N-005/02B; C12N-005/12B; C12N-015/63B DESIGNATED COUNTRIES: AE; AG; AL;  
AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK;  
DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE;  
KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ;  
NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT;  
TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM  
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW;  
AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR;  
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/12 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

137153822 CA: 137(11)153822s PATENT  
CD23 antagonistic antibodies for treatment of neoplastic disorders  
INVENTOR(AUTHOR): Hariharan, Kandasamy; Hanna, Nabil; Braslawsky, Gary R.  
; Pathan, Nuzhat  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200260484 A1 DATE: 20020808  
APPLICATION: WO 2002US2620 (20020131) \*US 772938 (20010131) \*US 855717  
(20010516) \*US 985646 (20011105)  
PAGES: 88 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-045/00A;  
A61K-045/06B; A61K-039/395B; A61P-035/00B; A61P-035/02B; A61K-039/395B;  
A61K-031/70B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;  
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO;  
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU;  
ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM  
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES;



FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/13 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

137139366 CA: 137(10)139366q PATENT  
Immunoregulatory antibodies and uses thereof  
INVENTOR(AUTHOR): Hariharan, Kandasamy; Hanna, Nabil  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200260485 A2 DATE: 20020808  
APPLICATION: WO 2002US2621 (20020131) \*US 772938 (20010131) \*US 855717 (20010516) \*US 985646 (20011105) \*US PV331187 (20011109)  
PAGES: 103 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-045/00A; A61K-045/06B; A61K-039/395B; A61P-035/00B; A61P-035/02B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/14 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136117380 CA: 136(8)117380s PATENT  
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications  
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200204021 A1 DATE: 20020117  
APPLICATION: WO 2001US15677 (20010516) \*US PV217706 (20000712) \*US 772938 (20010131)  
PAGES: 88 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395; C07K-016/32 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

7/3/15 (Item 6 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136101104 CA: 136(7)101104u PATENT  
Immunotherapy of B cell malignancies using a combination of cell depleting antibodies and antibodies to costimulatory molecules  
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation

PATENT: U.S. Pat. Appl. Publ. ; US 20020006404 A1 DATE: 20020117  
APPLICATION: US 772938 (20010131) \*US 435992 (19991108)  
PAGES: 27 pp., Cont.-in-part of U.S. Ser. No. 435,992. CODEN: USXXCO  
LANGUAGE: English CLASS: 424142100; A61K-039/395

7/3/16 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136068707 CA: 136(5)68707t PATENT  
Treatment of B-cell associated diseases such as malignancies and  
autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22  
antibody combination  
INVENTOR(AUTHOR): White, Christine  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200197858 A2 DATE: 20011227  
APPLICATION: WO 2001US18939 (20010614) \*US PV212668 (20000620)  
PAGES: 59 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-051/00A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;  
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;  
MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ  
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;  
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

7/3/17 (Item 8 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

134365708 CA: 134(26)365708x PATENT  
Treatment of B cell malignancies using anti-CD40L antibodies in  
combination with anti-CD20 antibodies and/or chemotherapeutics and  
radiotherapy  
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200134194 A1 DATE: 20010517  
APPLICATION: WO 2000US30426 (20001106) \*US 435992 (19991108)  
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;  
A61K-051/10B; A61P-035/02B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;  
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES;  
FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC;  
LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO;  
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW;  
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW  
; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;  
NE; SN; TD; TG

7/3/18 (Item 9 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

133149142 CA: 133(11)149142v PATENT  
Production of tetravalent antibodies  
INVENTOR(AUTHOR): Braslawsky, Gary Ronald; Hanna, Nabil; Hariharan,  
Kandasamy; Labarre, Michael J.; Huynh, Tri B.  
LOCATION: USA

ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200044788 A1 DATE: 20000803  
APPLICATION: WO 2000US1893 (20000128) \*US 238741 (19990128)  
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/00A;  
C07K-016/28B; C07K-016/46B; A61K-039/395B; A61P-035/00B; A61P-035/02B;  
A61P-037/00B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;  
BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ;  
TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;  
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT  
; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF;  
BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

7/3/19 (Item 10 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

133003706 CA: 133(1)3706k PATENT  
Membrane antigenic structure inducing stoppage of proliferation and  
apoptosis of activated T-lymphocytes  
INVENTOR(AUTHOR): Huez, Georges; Majjaj, Samira; Kruys, Veronique;  
Droogmans, Louis; Deblandre, Gisele  
LOCATION: Belg.  
ASSIGNEE: Universite Libre de Bruxelles  
PATENT: PCT International ; WO 200031138 A1 DATE: 20000602  
APPLICATION: WO 99BE149 (19991119) \*BE 98835 (19981119)  
PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: C07K-014/705A;  
C07K-016/28B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;  
BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD;  
MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM;  
TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;  
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE  
; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ;  
CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
? s (24(w)31 or 89(w)76 or c2b8) (20n) (antibod? or hybridoma?) and (Cd20 or cd40L or  
cd40(w)ligand or gp39)  
1301928 24  
503721 31  
1050 24(W)31  
201923 89  
229499 76  
94 89(W)76  
263 C2B8  
1807045 ANTIBOD?  
47845 HYBRIDOMA?  
210 ((24(W)31 OR 89(W)76) OR C2B8) (20N) (ANTIBOD? OR  
HYBRIDOMA?)  
10006 CD20  
4500 CD40L  
18006 CD40  
348210 LIGAND  
8235 CD40(W)LIGAND  
574 GP39  
S8 179 (24(W)31 OR 89(W)76 OR C2B8) (20N) (ANTIBOD? OR HYBRIDOMA?)  
AND (CD20 OR CD40L OR CD40(W)LIGAND OR GP39)  
?